Amneal Pharmaceuticals announced that it has entered into a definitive agreement to acquire Kashiv BioSciences, a move aimed at creating a fully integrated global biosimilars platform and expanding access to affordable biologic medicines.
The transaction combines Kashiv’s expertise in biosimilar development and manufacturing with Amneal’s commercial scale and distribution capabilities. The combined entity is expected to accelerate pipeline development and strengthen Amneal’s position in the U.S. and global biosimilars markets.
Kashiv BioSciences, headquartered in Piscataway, New Jersey, operates across the United States and India and is recognized for its vertically integrated capabilities spanning research and development, clinical trials, manufacturing, regulatory processes, and intellectual property. Amneal, based in Bridgewater, New Jersey, is a leading provider of affordable medicines with a broad portfolio of generics, specialty products, and biosimilars.
The acquisition comes at a time of significant growth in the biosimilars market, driven by an increasing number of biologic drugs losing exclusivity. This shift is expected to create substantial opportunities for companies capable of developing and commercializing cost-effective alternatives at scale.
By integrating Kashiv’s capabilities, Amneal aims to establish a differentiated platform capable of delivering a consistent pipeline of biosimilar launches while improving patient access to high-quality, lower-cost therapies. The combined platform is expected to enhance manufacturing efficiency, streamline development timelines, and expand global reach.
The transaction builds on a long-standing partnership between the two companies and is positioned as a strategic step in Amneal’s broader effort to become a leading diversified biopharmaceutical company.
The deal is subject to approval by Amneal shareholders, regulatory approvals, and customary closing conditions, with completion expected in the second half of 2026.
KEY QUOTES:
“We are thrilled to combine Kashiv’s highly complementary portfolio and capabilities with Amneal at this critical inflection point for the biosimilar market, particularly in the U.S. Our companies share a deep-rooted commitment to high-quality, complex medicines, and this transaction builds on the meaningful work we have accomplished through our partnership of more than ten years. We look forward to building on our proven track record of product approvals and advancing our biosimilars pipeline as we work together to expand patient access to life-changing therapies.”
Sandeep Athalye, Chief Executive Officer, Kashiv BioSciences
“As biosimilar adoption accelerates and the industry enters an unprecedented period of biologic loss of exclusivity, we see a compelling opportunity to establish leadership and scale in a rapidly expanding market. With Kashiv, Amneal becomes a fully integrated global biosimilars leader at the forefront of the next wave of U.S. affordable medicines. This acquisition is a natural next step in our strategy to build a leading, diversified biopharmaceutical company, and we are confident it will drive accelerated growth and long-term value creation.”
Chirag Patel, Co-Founder And Co-Chief Executive Officer, Amneal Pharmaceuticals
“This acquisition establishes Amneal as a fully integrated global biosimilar platform at scale. By combining Kashiv’s deep R&D and manufacturing capabilities with our commercial strength, we are creating a differentiated platform well-positioned to deliver a strong and consistent cadence of biosimilar launches going forward. Together, we will expand access to high-quality, affordable biologic medicines for patients while driving long-term growth.”
Chintu Patel, Co-Founder And Co-Chief Executive Officer, Amneal Pharmaceuticals
